Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

The number of mesenchymal stromal/stem cell (MSC) therapeutics and types of clinical applications have greatly diversified during the past decade, including rapid growth of poorly regulated “Stem Cell Clinics” offering diverse “Unproven Stem Cell Interventions.” This product diversification necessit...

Descripción completa

Detalles Bibliográficos
Autores principales: Moll, Guido, Ankrum, James A, Olson, Scott D, Nolta, Jan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895495/
https://www.ncbi.nlm.nih.gov/pubmed/35641163
http://dx.doi.org/10.1093/stcltm/szab005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895495/
https://www.ncbi.nlm.nih.gov/pubmed/35641163
http://dx.doi.org/10.1093/stcltm/szab005

Ejemplares similares